US spot Bitcoin ETFs experienced $1.28 billion in net outflows during Nov. 2–6, marking their biggest weekly withdrawal since June and pushing 2026 flows negative. BlackRock's iShares Bitcoin Trust led with $1.21 billion withdrawn, accounting for 95% of outflows, while Fidelity's fund saw inflows. Bitcoin's price fell below $76,000 amid market concerns including a major Binance hack, US midterm election uncertainty, and Federal Reserve rate expectations. Analysts warn Bitcoin may test support levels around $74,400–$75,000, with further declines possible if these fail. Investors will watch upcoming US inflation data and Fed signals for signs of institutional demand recovery.
Bitcoin ETFs' recent outflows provide context for cryptocurrency market trends on Pluang as of Nov 09, 2026 16:01 WIB. Of 50 major cryptocurrencies priced on Pluang, 6 rose and 43 fell today. Notable movers include XRP at Rp19.874 with a 1-day change of -5.56% and a typical hold time of 73 days, ETH at Rp38.399.211 down 5.02%, and ALGO at Rp1.637 down 4.94%, with ALGO showing the highest sell activity at 73%.
ISS A/S is actively executing its share buyback program announced in February 2026, aiming to redistribute excess cash to shareholders and reduce share capital. As of early November 2026, the company has repurchased approximately 7.69 million shares ...
AL Sydbank A/S executed transactions to buy back 30,000 shares during week 45 as part of its ongoing share buyback program announced in February 2026, which totals DKK 1.1 billion. The program started in March 2026 and will conclude by January 2027, ...
AL Sydbank A/S continued its share buyback program in week 45, purchasing 30,000 shares at an average price of around 725 DKK, totaling approximately 21.76 million DKK. The buyback program, announced in February 2026 and running until January 2027, a...
Oculis Holding AG announced an in-person and virtual R&D Day on December 8, 2026, to highlight key clinical developments in its late-stage pipeline, including Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmology and neurology. The...
Oculis Holding AG will hold a Research & Development Day on December 8, 2026, to present key clinical progress on its late-stage drug candidates Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmic conditions including optic neuritis...
